Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490698 | 0.84 | OPRL1 (0.38) | PLA2G2ANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL9848807 | 0.83 | PLA2G2A (0.44) | PLA2G2ANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL7140993 | 0.81 | CYP2D6 (0.42) | POLBKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL3490964 | 0.80 | KDM4E (0.38) | PLA2G2APOLBKDM4EALDH1A1TSHR | |
| SCHEMBL273928 | 0.80 | HSD17B10 (0.42) | POLBTSHRHSD17B10 | |
| SCHEMBL15548838 | 0.79 | KDM4E (0.41) | S1PR1POLBKDM4EALDH1A1TSHR | |
| SCHEMBL27707107 | 0.78 | PLA2G2A (0.37) | PLA2G2ANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL2245662 | 0.77 | LMNA (0.40) | S1PR1PLA2G2ANPC1RAB9APOLB | |
| SCHEMBL2544936 | 0.76 | PIK3CD (0.55) | S1PR1POLBKDM4EALDH1A1TSHR | |
| SCHEMBL23105622 | 0.76 | S1PR1 (0.49) | S1PR1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | GAILUNAS ANDREA | 2010-02-25 | — | — | US | disclosed |
| EP-1409450-B1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARM INC (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1409450-B1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARM INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589094-B2 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101068772-A | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARM INC (US) | 2007-11-07 | — | — | CN | disclosed |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | ELAN PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| EP-1409450-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | disclosed |
| WO-2003006423-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | BACE1, APP, BACE2 | S1PR1 2043/4885PLA2G2A 1173/4885NPC1 248/4885 |
| US-20060194817-A1 | N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds | BACE1, APP, BACE2 | S1PR1 2234/4885PLA2G2A 1190/4885NPC1 335/4885 |
| US-20100048590-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | BACE1, APP, BACE2 | S1PR1 2234/4885PLA2G2A 1190/4885NPC1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.